Search

Displaying results 1 - 10 of 28 in total
DrugBest match

Durvalumab

go.drugbank.com/drugs/DB11714
ApprovedInvestigational

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to prom...

  1. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma. … [A253717, A253722] After receiving an EMA Committee for Medicinal Products for Human Use (CHMP) recommendation in December 2022, tremelimumab was approved for combined use with [durvalumab].[L46188]

  2. Indication

    Gastroesophageal Junction Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0038020
    Drugs: Durvalumab
  3. Indication

    Locally Advanced Biliary Tract Cancer

    go.drugbank.com/conditions/DBCOND0046439
    Drugs: Durvalumab
  4. Indication

    Resectable Gastric Cancer

    go.drugbank.com/conditions/DBCOND0173768
    Drugs: Durvalumab
  5. Indication

    Stage 3 Locally Advanced Non-Small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0173359
    Drugs: Durvalumab
  6. Indication

    Small Cell Lung Cancer, Limited Stage

    go.drugbank.com/conditions/DBCOND0087944
    Drugs: Durvalumab
  7. Indication

    Unresectable Stage III Non-small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0123170
    Drugs: Durvalumab
  8. Indication

    Advanced mismatch repair proficient (pMMR) endometrial cancer

    go.drugbank.com/conditions/DBCOND0168677
    Drugs: Durvalumab
  9. Indication

    Primary advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer

    go.drugbank.com/conditions/DBCOND0173198
    Drugs: Durvalumab